Actinomycin D for reinduction of remission in dogs with resistant lymphoma.
Twenty-five dogs with malignant lymphoma refractory to chemotherapy were treated with actinomycin D at a median dose of 0.7 mg/m2 (range, 0.5 to 0.9 mg/m2) every 3 weeks. The dogs treated had received between 2 and 8 chemotherapeutic agents (median 7), for a median of 266 days before being treated with actinomycin D. For 23 of the 25 dogs, previous chemotherapy included doxorubicin. No dog responded to actinomycin D chemotherapy.
Department of Medicine, Tufts University School of Veterinary Medicine, North Grafton, MA 01536.
A S
AS
Moore
G K
GK
Ogilvie
D M
DM
Vail
D000818:Animals; D003609:Dactinomycin / Q000627:therapeutic use*; D004283:Dog Diseases / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D008223:Lymphoma / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D009367:Neoplasm Staging / Q000662:veterinary; D011379:Prognosis; D012074:Remission Induction
D003609:Dactinomycin; D004317:Doxorubicin